市場調查報告書

全球肝癌治療市場:癌症類型,治療,設備,年齡,因素,給藥途徑,分佈途徑,區域競爭情況,預測,機會

Global Liver Cancer Therapeutics Market, By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Distribution channel, By Region, Competition, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 952481
出版日期 內容資訊 英文 129 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

全球肝癌治療市場:癌症類型,治療,設備,年齡,因素,給藥途徑,分佈途徑,區域競爭情況,預測,機會 Global Liver Cancer Therapeutics Market, By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Distribution channel, By Region, Competition, Forecast & Opportunities, 2025
出版日期: 2020年08月01日內容資訊: 英文 129 Pages
簡介

預計全球肝癌治療市場將繼續穩定增長,到2025年達到110億美元。市場增長將受到全球越來越多的肝癌患者,酒精消費增加,人口老齡化以及公共和私營部門用於治療性研發的資金增加的推動。等因素。肝癌是一種慢性的,威脅生命的疾病,始於肝細胞。大多數肝癌患者在早期沒有出現症狀,但在晚期則表現出厭食症,上腹痛,噁心和嘔吐以及皮膚發黃等症狀。根據世界癌症研究基金會的資料,肝癌是世界第六大最常見的癌症。肝癌增加的另一個主要原因是HBV/HCV合併感染和肝硬化的發生率增加。

該報告調查了全球肝癌治療市場,該市場顯示了新型冠狀病毒傳染病(COVID-19)大流行的影響,全球和區域市場前景,市場動態,主要趨勢,我們提供諸如競爭情況之類的信息。

目錄

第1章產品概述

第2章調查方法

第3章COVID-19的影響

第4章客戶心聲

第5章執行摘要

第六章市場前景

  • 市場規模和預測
    • 金額基準
  • 市場佔有率和預測
    • 按癌症類型(肝細胞癌,膽管癌,肝母細胞瘤,血管肉瘤,肝轉移)
    • 按治療方法(靶向治療,化學療法和放射療法,免疫療法等)
    • 按設備(計算機射線照相,超聲檢查,MRI等)
    • 按年齡分類(0-18歲,18-35歲,35-50歲,50歲以上)
    • 按因素(肝硬化,非酒精性脂肪肝,過量飲酒等)
    • 按給藥途徑(口服,輸注等)
    • 按分銷渠道(醫院藥房,零售藥房,在線藥房)
    • 由公司
    • 按地區
  • 市場吸引力指數

第7章亞太市場展望

  • 市場規模和預測
  • 市場佔有率和預測
    • 按癌症類型分類
    • 按治療
    • 按設備
    • 按年齡
    • 按因子
    • 按管理途徑
    • 按國家
  • 國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第8章歐洲市場展望

  • 市場規模和預測
  • 市場佔有率和預測
    • 按癌症類型分類
    • 按治療
    • 按設備
    • 按年齡
    • 按因子
    • 按管理途徑
    • 按國家
  • 國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第9章北美

  • 市場規模和預測
  • 市場佔有率和預測
    • 按癌症類型分類
    • 按治療
    • 按設備
    • 按年齡
    • 按因子
    • 按管理途徑
    • 按國家
  • 國家分析
    • 美國
    • 墨西哥
    • 加拿大

第10章南美

  • 市場規模和預測
  • 市場佔有率和預測
    • 按癌症類型分類
    • 按治療
    • 按設備
    • 按年齡
    • 按因子
    • 按管理途徑
    • 按國家
  • 國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章中東和非洲

  • 市場規模和預測
  • 市場佔有率和預測
    • 按癌症類型分類
    • 按治療
    • 按設備
    • 按年齡
    • 按因子
    • 按管理途徑
    • 按國家
  • 國家分析
    • 南非
    • 沙特阿拉伯
    • 阿聯酋

第12章市場動態

  • 促銷促銷因素
  • 挑戰

第13章市場趨勢

第14章競爭情況

  • 競爭前景
  • 主要公司簡介
    • AbbVie Inc.
    • Alnylam Pharmaceuticals Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Celsion Corporation
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Exelixis, Inc.
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck
    • Novartis International AG
    • Perkin Elmer
    • Pfizer Inc.
    • Philips Healthcare Pvt. Ltd
    • Sanofi S.A.
    • Sun Pharmaceutical Industries Ltd.

第15章戰略建議

第16章免責聲明

目錄
Product Code: 4667

Global liver cancer therapeutics market is forecast to grow in the coming years and reach $ 11 billion by 2025. Major factors behind the growth of this market include rising cases of liver cancer, globally, increasing alcohol consumption, aging population, and growing funding by both public and private sector in research and development activities for cancer cure. Liver cancer is a chronic and life-threatening disease which begins in cells of liver. Most of the liver cancer patients do not show the symptoms at early stages but in later stages, the common symptoms include loss of appetite, upper abdominal pain, nausea and vomiting and yellow discoloration of skin. According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe. Another major reason for the increase in the liver cancer is the high increase in the incidence of HBV/HCV coinfection and cirrhosis. Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment. However, the market also faces some restrains. Expensive treatments as well as high cost in research and development might hamper further development of liver cancer therapeutics market.

The global liver cancer therapeutics market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region. Based on route of administration, the market is segmented into oral, intravenous and others. The oral segment is anticipated to dominate the global liver cancer therapeutics market during the forecast period as it is most preferred route of administration for chemotherapy. Based on distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies are anticipated to dominate the market during the forecast period as the drugs are mostly purchased from the hospitals at the time of treatment. Based on therapy the market is segmented into chemotherapy and radiation therapy, immunotherapy, targeted therapy, and others. The chemotherapy and radiation therapy segment is anticipated to dominate the market through 2025.

The onset of COVID-19 has adversely impacted the market on account of significantly lower patient footfall in private clinics and hospital OPDs. Major players operating in the global liver cancer therapeutics market include Bayer AG, Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche AG , Bristol-Myers Squibb Company, Eisai Co., Ltd. , Pfizer Inc., Exelixis, Inc., Merck, Celsion Corporation, Johnson & Johnson, Novartis International AG, Sanofi S.A., Eli Lilly and Company, Perkin Elmer, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., AstraZeneca, Philips Healthcare Pvt. Ltd and others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and forecast the market size of global liver cancer therapeutics market.
  • To classify and forecast global liver cancer therapeutics market based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • To identify drivers and challenges for global liver cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global liver cancer therapeutics market.
  • To conduct pricing analysis for global liver cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global liver cancer therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of leading players operating across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include market players, which could not be identified due to the limitations of secondary research. TechSci Research analyzed the market players, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global liver cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Liver cancer therapeutics players and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to liver cancer therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as market players, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global liver cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Cancer Type:

Hepatocellular Carcinoma

Cholangiocarcinoma

Hepatoblastoma

Angiosarcoma

Liver Metastasis

  • Market, By Therapy:

Targeted Therapy

Chemotherapy and Radiation Therapy

Immunotherapy

Others

  • Market, By Equipment:

Computed Radiography

Sonography

MRI

Others

  • Market, By Age:

0-18

18-35

35-50

50+

  • Market, By Factors:

Cirrhosis

Nonalcoholic Fatty Liver Disease

Excessive Alcohol Consumption

Others

  • Market, By Route of Administration:

Oral

Intravenous

Others

  • Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global liver cancer therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Liver Cancer Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Global Liver Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, Liver Metastasis)
    • 6.2.2. By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, Others)
    • 6.2.3. By Equipment (Computed Radiography, Sonography, MRI, Others)
    • 6.2.4. By Age (0-18, 18-35, 35-50, 50+)
    • 6.2.5. By Factors (Cirrhosis, Nonalcoholic Fatty Liver Disease, Excessive Alcohol Consumption, Others)
    • 6.2.6. By Route of Administration (Oral, Intravenous, Others)
    • 6.2.7. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.8. By Company (2019)
    • 6.2.9. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Liver Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapy
    • 7.2.3. By Equipment
    • 7.2.4. By Age
    • 7.2.5. By Factors
    • 7.2.6. By Route of Administration
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Liver Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Equipment
        • 7.3.1.2.4. By Age
        • 7.3.1.2.5. By Factors
        • 7.3.1.2.6. By Route of Administration
    • 7.3.2. India Liver Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Equipment
        • 7.3.2.2.4. By Age
        • 7.3.2.2.5. By Factors
        • 7.3.2.2.6. By Route of Administration
    • 7.3.3. Japan Liver Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Equipment
        • 7.3.3.2.4. By Age
        • 7.3.3.2.5. By Factors
        • 7.3.3.2.6. By Route of Administration
    • 7.3.4. South Korea Liver Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Equipment
        • 7.3.4.2.4. By Age
        • 7.3.4.2.5. By Factors
        • 7.3.4.2.6. By Route of Administration
    • 7.3.5. Australia Liver Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Equipment
        • 7.3.5.2.4. By Age
        • 7.3.5.2.5. By Factors
        • 7.3.5.2.6. By Route of Administration

8. Europe Liver Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapy
    • 8.2.3. By Equipment
    • 8.2.4. By Age
    • 8.2.5. By Factors
    • 8.2.6. By Route of Administration
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Liver Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Equipment
        • 8.3.1.2.4. By Age
        • 8.3.1.2.5. By Factors
        • 8.3.1.2.6. By Route of Administration
    • 8.3.2. Germany Liver Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Equipment
        • 8.3.2.2.4. By Age
        • 8.3.2.2.5. By Factors
        • 8.3.2.2.6. By Route of Administration
    • 8.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Equipment
        • 8.3.3.2.4. By Age
        • 8.3.3.2.5. By Factors
        • 8.3.3.2.6. By Route of Administration
    • 8.3.4. Italy Liver Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Equipment
        • 8.3.4.2.4. By Age
        • 8.3.4.2.5. By Factors
        • 8.3.4.2.6. By Route of Administration
    • 8.3.5. Spain Liver Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Equipment
        • 8.3.5.2.4. By Age
        • 8.3.5.2.5. By Factors
        • 8.3.5.2.6. By Route of Administration

9. North America Liver Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapy
    • 9.2.3. By Equipment
    • 9.2.4. By Age
    • 9.2.5. By Factors
    • 9.2.6. By Route of Administration
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Liver Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Equipment
        • 9.3.1.2.4. By Age
        • 9.3.1.2.5. By Factors
        • 9.3.1.2.6. By Route of Administration
    • 9.3.2. Mexico Liver Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Equipment
        • 9.3.2.2.4. By Age
        • 9.3.2.2.5. By Factors
        • 9.3.2.2.6. By Route of Administration
    • 9.3.3. Canada Liver Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Equipment
        • 9.3.3.2.4. By Age
        • 9.3.3.2.5. By Factors
        • 9.3.3.2.6. By Route of Administration

10. South America Liver Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapy
    • 10.2.3. By Equipment
    • 10.2.4. By Age
    • 10.2.5. By Factors
    • 10.2.6. By Route of Administration
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Equipment
        • 10.3.1.2.4. By Age
        • 10.3.1.2.5. By Factors
        • 10.3.1.2.6. By Route of Administration
    • 10.3.2. Argentina Liver Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Equipment
        • 10.3.2.2.4. By Age
        • 10.3.2.2.5. By Factors
        • 10.3.2.2.6. By Route of Administration
    • 10.3.3. Colombia Liver Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Equipment
        • 10.3.3.2.4. By Age
        • 10.3.3.2.5. By Factors
        • 10.3.3.2.6. By Route of Administration

11. Middle East and Africa Liver Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Cancer Type
    • 11.2.2. By Therapy
    • 11.2.3. By Equipment
    • 11.2.4. By Age
    • 11.2.5. By Factors
    • 11.2.6. By Route of Administration
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Liver Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Cancer Type
        • 11.3.1.2.2. By Therapy
        • 11.3.1.2.3. By Equipment
        • 11.3.1.2.4. By Age
        • 11.3.1.2.5. By Factors
        • 11.3.1.2.6. By Route of Administration
    • 11.3.2. Saudi Arabia Liver Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Cancer Type
        • 11.3.2.2.2. By Therapy
        • 11.3.2.2.3. By Equipment
        • 11.3.2.2.4. By Age
        • 11.3.2.2.5. By Factors
        • 11.3.2.2.6. By Route of Administration
    • 11.3.3. UAE Liver Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Cancer Type
        • 11.3.3.2.2. By Therapy
        • 11.3.3.2.3. By Equipment
        • 11.3.3.2.4. By Age
        • 11.3.3.2.5. By Factors
        • 11.3.3.2.6. By Route of Administration

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. AbbVie Inc.
    • 14.2.2. Alnylam Pharmaceuticals Inc.
    • 14.2.3. Amgen Inc.
    • 14.2.4. AstraZeneca
    • 14.2.5. Bayer AG
    • 14.2.6. Bristol-Myers Squibb Company
    • 14.2.7. Celsion Corporation
    • 14.2.8. Eisai Co., Ltd.
    • 14.2.9. Eli Lilly and Company
    • 14.2.10. Exelixis, Inc.
    • 14.2.11. F. Hoffmann-La Roche AG
    • 14.2.12. Johnson & Johnson
    • 14.2.13. Merck
    • 14.2.14. Novartis International AG
    • 14.2.15. Perkin Elmer
    • 14.2.16. Pfizer Inc.
    • 14.2.17. Philips Healthcare Pvt. Ltd
    • 14.2.18. Sanofi S.A.
    • 14.2.19. Sun Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Figures

  • Figure 1: Global Liver Cancer Therapeutic Market Size, By Value, 2015-2025F (USD Million)
  • Figure 2: Global Per Capita Health Expenditure, In USD, 2015-2019
  • Figure 3: Global Liver Cancer Therapeutic Market Share, By Cancer Type, By Value, 2015-2025F
  • Figure 4: Global Liver Cancer Therapeutic Market Share, By Therapy, By Value, 2015-2025F
  • Figure 5: Global Liver Cancer Therapeutic Market Share, By Equipment, By Value, 2015-2025F
  • Figure 6: Global Liver Cancer Therapeutic Market Share, By Age, By Value, 2015-2025F
  • Figure 7: Global Liver Cancer Therapeutic Market Share, By Factors, By Value, 2015-2025F
  • Figure 8: Global Liver Cancer Therapeutic Market Share, By Route of Administration, By Value, 2019 & 2025F
  • Figure 9: Global Liver Cancer Therapeutic Market Share, By Distribution Channel, By Value, 2019 & 2025F
  • Figure 10: Global Liver Cancer Therapeutic Market Share, By Region, By Value, 2019 & 2025F
  • Figure 11: Global Liver Cancer Therapeutic Market Share, By Company, By Value, 2019
  • Figure 12: Global Liver Cancer Therapeutics Market Size (USD Billion) & Growth Rate (%), By Cancer Type, 2020E-2025F
  • Figure 13: Global Liver Cancer Therapeutics Market Size (USD Billion) & Growth Rate (%), By Therapy, 2020E-2025F
  • Figure 14: Global Liver Cancer Therapeutics Market Size (USD Billion) & Growth Rate (%), By Region, 2020E-2025F
  • Figure 15: Asia-Pacific Liver Cancer Therapeutic Market Size, By Value, 2015-2025F (USD Million)
  • Figure 16: Asia Pacific Liver Cancer Therapeutics Market Share, By Cancer Type, By Value, 2015-2025F
  • Figure 17: Asia Pacific Liver Cancer Therapeutic Market Share, By Therapy, By Value, 2015-2025F
  • Figure 18: Asia Pacific Liver Cancer Therapeutic Market Share, By Equipment, By Value, 2015-2025F
  • Figure 19: Asia Pacific Liver Cancer Therapeutic Market Share, By Age, By Value, 2015-2025F
  • Figure 20: Asia Pacific Cancer Therapeutic Market Share, By Factors, By Value, 2015-2025F
  • Figure 21: Asia Pacific Liver Cancer Therapeutic Market Share, By Route of Administration, By Value, 2019 & 2025F
  • Figure 22: Asia Pacific Liver Cancer Therapeutic Market Share, By Country, By Value, 2019 & 2025F
  • Figure 23: Japan Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 24: Japan Total Health Expenditure as a share of GDP, 2015- 2019
  • Figure 25: Japan Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 26: Japan Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 27: Japan Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 28: Japan Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 29: Japan Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 30: Japan Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 31: China Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 32: China Number of Health Checks, By Volume, 2012, 2015, 2017, 2019, 2020E, 2025F (Billion)
  • Figure 33: China Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 34: China Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 35: China Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 36: China Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 37: China Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 38: China Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 39: India Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 40: India No of Hospitalized Cases For The Treatment of Patients, 2008, 2013 & 2019
  • Figure 41: India Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 42: India Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 43: India Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 44: India Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 45: India Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 46: India Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 47: South Korea Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Billion)
  • Figure 48: South Korea Per Capita Expenditure On Health, By Value, '000 USD, 2015-2020E
  • Figure 49: South Korea Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 50: South Korea Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 51: South Korea Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 52: South Korea Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 53: South Korea Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 54: South Korea Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 55: Australia Liver Cancer Therapeutics Market Size, By Value 2015-2025F (USD Billion)
  • Figure 56: Australia Enterprise Healthcare Spending, By Value (USD Billion) 2017-2021E
  • Figure 57: Australia Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 58: Australia Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 59: Australia Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 60: Australia Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 61: Australia Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 62: Australia Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 63: Europe Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Billion)
  • Figure 64: Europe Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 65: Europe Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 66: Europe Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 67: Europe Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 68: Europe Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 69: Europe Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 70: Europe Liver Cancer Therapeutics Market Size, By Country, 2015-2025F
  • Figure 71: Germany Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Billion)
  • Figure 72: Germany New Cases of Cancer, By Type, 2019
  • Figure 73: Germany Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 74: Germany Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 75: Germany Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 76: Germany Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 77: Germany Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 78: Germany Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 79: France Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 80: France Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 81: France Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 82: France Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 83: France Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 84: France Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 85: France Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 86: United Kingdom Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 87: United Kingdom Healthcare Spending, By Value (USD Per Capita), 2015-2018
  • Figure 88: United Kingdom Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 89: United Kingdom Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 90: United Kingdom Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 91: United Kingdom Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 92: United Kingdom Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 93: United Kingdom Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 94: Italy Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 95: Italy Per Capita Expenditure On Health, By Value, '000 USD, 2015-2020E
  • Figure 96: Italy Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 97: Italy Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 98: Italy Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 99: Italy Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 100: Italy Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 101: Italy Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 102: Spain Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 103: Spain Hospital Beds, By Volume, 2014-2020E
  • Figure 104: Spain Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 105: Spain Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 106: Spain Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 107: Spain Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 108: Spain Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 109: Spain Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 110: North America Liver Cancer Therapeutics Market Size, By Value
  • Figure 111: North America Health Spending Share, By Value, 2020E
  • Figure 112: North America Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 113: North America Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 114: North America Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 115: North America Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 116: North America Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 117: North America Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 118: North America Liver Cancer Therapeutics Market Size, By Country, 2015-2025F
  • Figure 119: United States Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 120: United States Healthcare Spending, By Value, 2018 -2021F (USD Per Capita)
  • Figure 121: United States Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 122: United States Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 123: United States Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 124: United States Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 125: United States Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 126: United States Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 127: Canada Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 128: Canada Hospital Establishments, By Region, 2019 (Units)
  • Figure 129: Canada Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 130: Canada Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 131: Canada Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 132: Canada Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 133: Canada Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 134: Canada Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 135: Mexico Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 136: Mexico Promotional Mortality (Percentage of All Deaths, By Disease, 2019
  • Figure 137: Mexico Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 138: Mexico Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 139: Mexico Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 140: Mexico Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 141: Mexico Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 142: Mexico Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 143: South America Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Billion)
  • Figure 144: South America Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 145: South America Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 146: South America Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 147: South America Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 148: South America Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 149: South America Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 150: South America Liver Cancer Therapeutics Market Size, By Country, 2015-2025F
  • Figure 151: Brazil Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 152: Brazil Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 153: Brazil Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 154: Brazil Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 155: Brazil Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 156: Brazil Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 157: Brazil Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 158: Argentina Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 159: Argentina, Per Capita Health Expenditure, By Sector (USD), 2020E
  • Figure 160: Argentina Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 161: Argentina Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 162: Argentina Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 163: Argentina Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 164: Argentina Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 165: Argentina Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 166: Colombia Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 167: Colombia Healthcare Expenditure, By Value, USD Billion, 2015-2020E
  • Figure 168: Colombia Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 169: Colombia Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 170: Colombia Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 171: Colombia Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 172: Colombia Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 173: Colombia Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 174: Middle East & Africa Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Billion)
  • Figure 175: Middle East & Africa Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 176: Middle East & Africa Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 177: Middle East & Africa Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 178: Middle East & Africa Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 179: Middle East & Africa Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 180: Middle East & Africa Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 181: Middle East & Africa Liver Cancer Therapeutics Market Size, By Country, 2015-2025F
  • Figure 182: South Africa Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 183: South Africa per Capita Health Expenditure, 2014-2016, 2019 & 2020E (USD)
  • Figure 184: South Africa Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 185: South Africa Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 186: South Africa Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 187: South Africa Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 188: South Africa Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 189: South Africa Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 190: Saudi Arabia Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 191: Saudi Arabia Healthcare Budget, By Value (USD Billion),2018 & 2019
  • Figure 192: Saudi Arabia Covid-19 Cumulative Statistics, By Value, Till 13th May 2020
  • Figure 193: Saudi Arabia Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 194: Saudi Arabia Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 195: Saudi Arabia Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 196: Saudi Arabia Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 197: Saudi Arabia Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 198: Saudi Arabia Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F
  • Figure 199: UAE Liver Cancer Therapeutics Market Size, By Value, 2015-2025F (USD Million)
  • Figure 200: UAE Healthcare Expenditure, By Value (USD Billion), 2018, 2019, 2023F & 2028F
  • Figure 201: UAE Covid-19 Cumulative Statistics, By Value, Till 13th May 2020
  • Figure 202: UAE Liver Cancer Therapeutics Market Share, By Type, By Value, 2015-2025F
  • Figure 203: UAE Liver Cancer Therapeutics Market Share, By Therapy, By Value, 2015-2025F
  • Figure 204: UAE Liver Cancer Therapeutics Market Share, By Equipment, By Value, 2015-2025F
  • Figure 205: UAE Liver Cancer Therapeutics Market Share, By Age, By Value, 2015-2025F
  • Figure 206: UAE Liver Cancer Therapeutics Market Share, By Factors, By Value, 2015-2025F
  • Figure 207: UAE Liver Cancer Therapeutics Market Share, By ROA, By Value, 2015-2025F